These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 37869749)

  • 1. Bedside to bench: the outlook for psychedelic research.
    Acero VP; Cribas ES; Browne KD; Rivellini O; Burrell JC; O'Donnell JC; Das S; Cullen DK
    Front Pharmacol; 2023; 14():1240295. PubMed ID: 37869749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Registered clinical studies investigating psychedelic drugs for psychiatric disorders.
    Siegel AN; Meshkat S; Benitah K; Lipsitz O; Gill H; Lui LMW; Teopiz KM; McIntyre RS; Rosenblat JD
    J Psychiatr Res; 2021 Jul; 139():71-81. PubMed ID: 34048997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
    Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
    Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.
    Kozlowska U; Nichols C; Wiatr K; Figiel M
    J Neurochem; 2022 Jul; 162(1):89-108. PubMed ID: 34519052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelics and Other Psychoplastogens for Treating Mental Illness.
    Vargas MV; Meyer R; Avanes AA; Rus M; Olson DE
    Front Psychiatry; 2021; 12():727117. PubMed ID: 34671279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.
    Caspani G; Ruffell SGD; Tsang W; Netzband N; Rohani-Shukla C; Swann JR; Jefferies WA
    Pharmacol Res; 2024 Sep; 207():107338. PubMed ID: 39111558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder.
    Velit-Salazar MR; Shiroma PR; Cherian E
    Brain Sci; 2024 Mar; 14(3):. PubMed ID: 38539636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelic-inspired approaches for treating neurodegenerative disorders.
    Saeger HN; Olson DE
    J Neurochem; 2022 Jul; 162(1):109-127. PubMed ID: 34816433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the regulatory framework of psychedelics in the US & Europe.
    Behera HK; Joga R; Yerram S; Karnati P; Mergu T; Gandhi K; M S; Nathiya D; Singh RP; Srivastava S; Kumar S
    Asian J Psychiatr; 2024 Sep; 102():104242. PubMed ID: 39305768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Default Mode Network Modulation by Psychedelics: A Systematic Review.
    Gattuso JJ; Perkins D; Ruffell S; Lawrence AJ; Hoyer D; Jacobson LH; Timmermann C; Castle D; Rossell SL; Downey LA; Pagni BA; Galvão-Coelho NL; Nutt D; Sarris J
    Int J Neuropsychopharmacol; 2023 Mar; 26(3):155-188. PubMed ID: 36272145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Psychedelics in Treating Anxiety Disorders.
    Feulner L; Sermchaiwong T; Rodland N; Galarneau D
    Ochsner J; 2023; 23(4):315-328. PubMed ID: 38143548
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review.
    Fonseka LN; Woo BK
    World J Psychiatry; 2023 May; 13(5):182-190. PubMed ID: 37303932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
    Chi T; Gold JA
    J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.